Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Breaks Out OTC Sales Figures In Bid To Play Up Diversification

This article was originally published in The Tan Sheet

Executive Summary

Teva Pharmaceutical Industries reported OTC product sales for the first time Feb. 15. The Jerusalem firm said OTC net revenue was $765 million in 2011, up 54.2% and attributable largely to the acquisition of German firm ratiopharm and the PGT Healthcare joint venture with Procter & Gamble.

You may also be interested in...

People In Brief

Bristol-Myers exec to head Teva; GSK’s Witty now Sir Andrew; ISPE names Berg president; more People In Brief.

PGT Healthcare Aims To Unlock Value Of Existing Portfolios

PGT Healthcare CEO Briain de Buitleir and COO Eli Shani say the joint venture will help Teva realize greater value for its localized OTCs and enable Procter & Gamble to expand its nutritional products portfolio.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts